Chi Viet, DDS, MD, PhD, FACS’ Post

A Milestone in Treating Ovarian Cancer: FDA Grants Full Approval to Elahere The FDA has granted full approval to Elahere, an antibody-drug conjugate (ADC), for the treatment of FRα-positive, platinum-resistant ovarian cancer. Elahere is the first and only ADC approved for this indication in the United States. The approval is seen as a significant breakthrough in the field of oncology and offers new hope for patients with this challenging malignancy. The SORAYA trial demonstrated Elahere's anti-tumor activity and tolerability, with 31.7% of patients achieving a confirmed objective response rate. The MIRASOL trial further supported Elahere's efficacy, showing superiority in overall survival and progression-free survival compared to chemotherapy. This approval marks a milestone in the treatment landscape for ovarian cancer and highlights the importance of targeted therapies in addressing unmet medical needs. For more details please click the link! https://lnkd.in/dm_-PYut #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Daiichi Sankyo US and AstraZeneca Reveal Data from the P-III (DESTINY-Breast06) Trial of Enhertu for Treating Breast Cancer  #daiichisankyo #astrazeneca #enhertu #breastcancer #clinicaltrial #phase3 #safety #efficacy #chemotherapy #treatment #capecitabine #paclitaxel

Urothelial Cancer Treatments PADCEV® and KEYTRUDA® Were Validated Type II Variation Applications by EMA EMA has validated a Type II variation application for PADCEV® (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) as a first-line therapy for urothelial cancer. This combination therapy offers an alternative to platinum-containing chemotherapy and has shown significant improvements in overall survival and progression-free survival. The next steps involve review by the EMA's CHMP and EC. This therapy has already been approved by the FDA in the United States. The validation represents a promising step toward offering bladder cancer patients in Europe a new treatment option. For more details please click the link! https://lnkd.in/d-YV7rFS #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/wBW030sErib

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/lrhX30sEbSy

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/VPb730sEi61

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/yHIe30sEeVN

Mark your calendars for the 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference in London, endorsed by Medicon Valley Alliance as Our Supporting Association Partners. Join us on 07th-8th March 2024 at Park Plaza Victoria to explore the forefront of cancer immunotherapy To explore more, click here: https://lnkd.in/dvuWh2a6 #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets  

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/Jmmk30sEb6I

Join us for an exclusive first look at our two-year stability study of a complete fulvestrant application on Tuesday 25 June. Fulvestrant, crucial in treating advanced breast cancer, binds, blocks, and degrades oestrogen receptors but is notoriously poorly water-soluble. How can formulators optimise their oncology treatments? Join to find out. What’s in it for you? ➊ Discover how excipients of different purity interact with fulvestrant ➋ Understand how this stability data can transform the way you store and manage your formulations. ➌ Gain insights that have never been shared publicly until now. ➍ This is a unique opportunity to deepen your knowledge and enhance your formulation techniques with data that could significantly impact the efficacy and stability of your oncology treatments! This webinar will also cover more API stability data, along with a preview of our large molecule therapy development for oncology offering, such as mAbs and nucleic acid-based cancer therapies, plus upstream to downstream biomanufacturing. Webinar date: Tuesday 25 June Register here: https://ow.ly/ULO230sErBY